Prospects for pharmacological treatment of transmissible subacute spongiform encephalopathies;Perspectives therapeutiques des encephalopathies subaigues spongiformes transmissibles

Revue du Praticien

Volumn 49, Issue 9, 1999, Pages 971-975

  Seman, Michel ^a,b   Adjou, Karim Tarik ^b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Laboratoires Mayoly Spindler   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE; CONGO RED; MS 8209; POLYANION; POLYENE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTIVIRUS AGENT; DRUG DERIVATIVE; POLYANIONS; POLYMER;

ARTICLE; CREUTZFELDT JAKOB DISEASE; PRION DISEASE; SURVIVAL TIME; DISEASE COURSE; HUMAN; PATHOLOGY; PROGNOSIS; REVIEW;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIVIRAL AGENTS; CREUTZFELDT-JAKOB SYNDROME; DISEASE PROGRESSION; HUMANS; POLYMERS; PROGNOSIS;

EID: 0033135148     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cousens SN, Vynnycky E, Zeidier M et al. Predicting the CJD epidemic in humans. Nature 1997 ; 385 : 197-8.
2. Brown P.A therapeutic panorama of the spongiform encephalopathies. Antiviral Chemistry Chemother 1990 ; 1 : 75-83.
3. Dormont D, Yeramian P, Lambert P et al. In vitro and in vivo antiviral effects of HPA23. In Unconventional virus diseases of the central nervous system. 1939, Fontenay-aux-Roses:CEA Diffusion : 324-37.
4. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by Impairment of agent replication in spleen. J GenVirol 1984 ; 65 : 1325-30.
5. Ladogana A, Casaccia P, Ingrosso L et al. Sulphate polyanions prolong incubation period of scrapie infected hamsters. J Gen Virol 1992 ; 73 : 661-5.
6. Caughey B. Scraple associated PrP accumulation and its prevention: Insights from cell culture. British Med Bull 1993 ; 49 : 860-72.
7. Ingrosso L, Ladogana A, Pocchiari M et al. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995 ; 69(1) : 506-8.
8. Tagliavini F, McArthur RA, Canciani B et al. Effectiveness of Anthracycline against experimental prion disease in Syrian hamsters. Science 1997 ; 276 : 1119-22.
9. Pocchiari M, Schmittinger S, Masulo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters J Gen Virol 1987 ; 68 : 219-23.
10. Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989 ; 160 : 795-802.
11. McKenzle D, Kacszkowski J, Marsh R, Alken J.Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J Virol 1994 ; 68 : 7534-6.
12. Demaimay R, Adjou K, Lasmézas C et al. Pharmacological studies of a new derivative of Amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 1994 ; 75 : 2499-503.
13. Masullo C, Macchi G, XiYG, Pocchiarl M. Failure to ameliorate Creutzfeldt-jakob disease with amphotericin B therapy. J Infect Dis 1992 ; 165 : 784-5.
14. Demaimay R, Adjou KT, Beringue V et al. Late treatment with polyene antibiotics can prolong the survival time of the scrapie-infected animals. J Virol 1997 ; 71 : 9685-9.
15. Ellis WG, Sobel RA, Nielson SL. Leukoencephalopathy in patients treated with amphotericin B methylester. J Infect Dis 1982 ; 146 : 125-7.
16. Saint Julien L, Joly V, Seman M, Carbon C, Yeni P. Activity of MS-8209, a nonester Amphotericin B derivative, in treatment of experimental systemic mycoses.Antimicrob Agents Chemother 1992 ; 36 : 2722-8.
17. Adjou KT, Demaimay R, Lasmézas C, Deslys JP, Seman M, Dormont D. MS-8209, a new Amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 1995 ; 39 : 2810-2.
18. Adjou KT, Demaimay R, Lasmézas C, Seman M, Desiys JP, Dormont D. Differential effects of a new Amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res Virol 1996 ; 147 : 213-18.
19. Adjou KT, Deslys JP, Demaimay R, Dormont D. Probing the dynamics of prion diseases with amphotericin B. Trends Microblol 1997 ; 5(1) : 27-31.
20. Cohen FE, Pan KM, Huang Z et al. Structural clues to prion replication. Science 1994 ; 264 : 530-1.
21. Telling, GC, Scott M, Mastrianni J et al. Prion propagation in mice expressing human and chimeric PrP transgenes Implicates the interaction of cellular PrP with another protein. Cell 1995 ; 83 : 79-90.
22. Kaneko K, Vey M, Scott M et al. COOH-terminal sequence of the cellular prion protein directs subcellular traficking and controls conversion into the scrapie isoform. Proc Natl Acad Sci USA 1997 ; 94 : 2333-8.
23. Chabry J, Caughey B, Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998 ; 273 : 13203-7.
24. Soto C, Sigurdsson Elnar M, Morelli L et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implication for Alzheimer's therapy. Nature Med 1998 ; 4 : 822-6.